BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Clinical trial NCT06741072 · RECRUITING

Trial details

NCT number: NCT06741072
Sponsor: Ohio State University Comprehensive Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Chronic Kidney Disease, Stage 4 Chronic Kidney Disease, Stage 5 EBV-Related Lymphoproliferative Disorder EBV-Related Malignant Neoplasm Post-Transplant Lymphoproliferative Disorder

Start date: 2026-06-28
Primary completion: 2027-07-31
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.